Analysts See $0.81 EPS for PRA Health Sciences Inc (PRAH)

October 13, 2017 - By reb123z

 Analysts See $0.81 EPS for PRA Health Sciences Inc (PRAH)

Analysts await PRA Health Sciences Inc (NASDAQ:PRAH) to report earnings on November, 1. They expect $0.81 EPS, up 30.65 % or $0.19 from last year’s $0.62 per share. PRAH’s profit will be $50.71 million for 25.34 P/E if the $0.81 EPS becomes a reality. After $0.62 actual EPS reported by PRA Health Sciences Inc for the previous quarter, Wall Street now forecasts 30.65 % EPS growth. The stock increased 0.82% or $0.67 during the last trading session, reaching $82.11. About 338,886 shares traded. PRA Health Sciences Inc (NASDAQ:PRAH) has risen 52.22% since October 13, 2016 and is uptrending. It has outperformed by 35.52% the S&P500.

PRA Health Sciences Inc (NASDAQ:PRAH) Ratings Coverage

Among 12 analysts covering PRA Health Sciences (NASDAQ:PRAH), 8 have Buy rating, 0 Sell and 4 Hold. Therefore 67% are positive. PRA Health Sciences had 23 analyst reports since July 22, 2015 according to SRatingsIntel. As per Thursday, November 19, the company rating was initiated by SunTrust. The firm has “Outperform” rating given on Tuesday, August 8 by Credit Suisse. The stock of PRA Health Sciences Inc (NASDAQ:PRAH) earned “Overweight” rating by KeyBanc Capital Markets on Monday, June 13. As per Thursday, November 19, the company rating was initiated by Suntrust Robinson. The stock of PRA Health Sciences Inc (NASDAQ:PRAH) has “Neutral” rating given on Tuesday, June 21 by Credit Suisse. The rating was upgraded by Credit Suisse to “Outperform” on Monday, February 6. The firm has “Buy” rating by Citigroup given on Thursday, September 22. The stock of PRA Health Sciences Inc (NASDAQ:PRAH) has “Buy” rating given on Monday, October 9 by Robert W. Baird. The stock has “Outperform” rating by Credit Suisse on Friday, August 14. The firm has “Equal-Weight” rating given on Tuesday, June 21 by First Analysis.

PRA Health Sciences, Inc. is a contract research organization. The company has market cap of $5.14 billion. The Firm provides outsourced clinical development services to the biotechnology and pharmaceutical industries. It has a 53.38 P/E ratio. The Firm offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

More notable recent PRA Health Sciences Inc (NASDAQ:PRAH) news were published by: Prnewswire.com which released: “Medical Research Stock Performance Review — OpGen, TearLab, TrovaGene, and …” on September 29, 2017, also Globenewswire.com with their article: “PRA Health Sciences to acquire Symphony Health Solutions, a leading provider …” published on August 07, 2017, Globenewswire.com published: “PRA Health Sciences, Inc. Reports Second Quarter 2017 Results and Updates Full …” on August 07, 2017. More interesting news about PRA Health Sciences Inc (NASDAQ:PRAH) were released by: Seekingalpha.com and their article: “PRA Health Sciences’ (PRAH) CEO Colin Shannon on Q1 2017 Results – Earnings …” published on April 26, 2017 as well as Seekingalpha.com‘s news article titled: “PRA Health Sciences Set For A Quarterly Earnings Surprise – Again” with publication date: July 26, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.